EGFR and colorectal carcinoma: Moreover, therapeutic resistance, which occurs in nearly 80% of advanced CRC cases, is frequently mediated through the compensatory activation of alternative pathways, such as the PI3K/Akt and Ras/Raf/MEK/ERK pathways, both of which are closely interconnected with EGFR signaling.